Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors

Breast cancer (BC) is a lethal malignancy with high morbidity and mortality but lacks effective treatments thus far. Despite the introduction of immune checkpoint inhibitors (ICIs) (including PD-1/PD-L1 inhibitors), durable and optimal clinical benefits still remain elusive for a considerable number...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuqian, Lu, Lingeng, Ling, Changquan, Zhang, Ping, Han, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537481/
https://www.ncbi.nlm.nih.gov/pubmed/37764768
http://dx.doi.org/10.3390/nu15183984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537481/
https://www.ncbi.nlm.nih.gov/pubmed/37764768
http://dx.doi.org/10.3390/nu15183984

Ejemplares similares